Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and efficacy of olanzapine treatment in psychosis: effect of genetic and epigenetic factors
2018-002267-25Phase 4Completed
- Sponsor
- Fakultní nemocnice Brno
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of olanzapine in schizophrenia and schizoaffective disorder, sponsored by Fakultní nemocnice Brno. Primary endpoint: Genetic and epigenetic background endpoints. Started Jun 2018; status: completed.
02
Drugs
olanzapine
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on 2018-002267-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002267-25.